These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33529722)

  • 1. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World.
    Greenhawt M; Abrams EM; Oppenheimer J; Vander Leek TK; Mack DP; Singer AG; Shaker M
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1438-1441. PubMed ID: 33529722
    [No Abstract]   [Full Text] [Related]  

  • 2. [MANAGEMENT, DIAGNOSIS, AND TREATMENT OF SEVERE ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS TO COVID-19 VACCINE].
    Asano K; Fujisawa T; Nakamura Y; Nagata M; Hide M; Fujieda S
    Arerugi; 2021; 70(3):215-223. PubMed ID: 34011777
    [No Abstract]   [Full Text] [Related]  

  • 3. [Not Available].
    Klimek L; Chaker AM; Cuevas M
    Laryngorhinootologie; 2021 May; 100(5):344-354. PubMed ID: 33684947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.
    Shaker M; Phillips E; Blumenthal KG; Abrams EM; Banerji A; Oppenheimer J; Vander Leek TK; Mack DP; Wickner PG; Singer AG; Khan DA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2556-2561. PubMed ID: 33892171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinating against covid-19 in people who report allergies.
    Glover RE; Urquhart R; Lukawska J; Blumenthal KG
    BMJ; 2021 Jan; 372():n120. PubMed ID: 33461962
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?".
    Cabanillas B; Akdis CA; Novak N
    Allergy; 2021 Jun; 76(6):1938-1940. PubMed ID: 34128561
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Somiya M; Mine S; Yasukawa K; Ikeda S
    Vaccine; 2021 Jun; 39(25):3313-3314. PubMed ID: 34020815
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
    Peter J
    S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation.
    Jaggers J; Wolfson AR
    Curr Allergy Asthma Rep; 2023 Mar; 23(3):195-200. PubMed ID: 36689047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaphylaxis-related knowledge and concerns in Canadian families during the coronavirus disease 2019 pandemic.
    Gabrielli S; Protudjer JLP; Gooding G; Gerdts J; Ben-Shoshan M
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):496-497. PubMed ID: 34260902
    [No Abstract]   [Full Text] [Related]  

  • 12. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic.
    Senna G; Caminati M; Castells M
    Curr Opin Allergy Clin Immunol; 2020 Oct; 20(5):429-430. PubMed ID: 32739982
    [No Abstract]   [Full Text] [Related]  

  • 14. Ascertainment Bias in Anaphylaxis Safety Data of COVID-19 Vaccines.
    Hourihane JO; Byrne AM; Blümchen K; Turner PJ; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2562-2566. PubMed ID: 34246432
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 vaccine anaphylaxis: PEG or not?
    Krantz MS; Liu Y; Phillips EJ; Stone CA
    Allergy; 2021 Jun; 76(6):1934-1937. PubMed ID: 34128562
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines.
    Murphy KR; Patel NC; Ein D; Hudelson M; Kodoth S; Marshall GD; Parikh P; Blaiss MS
    Ann Allergy Asthma Immunol; 2021 Apr; 126(4):319-320. PubMed ID: 33493641
    [No Abstract]   [Full Text] [Related]  

  • 17. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine.
    Smola A; Samadzadeh S; Müller L; Adams O; Homey B; Albrecht P; Meller S
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e743-e745. PubMed ID: 34310766
    [No Abstract]   [Full Text] [Related]  

  • 19. An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history.
    Krantz MS; Stone CA; Rolando LA; Nobis AE; Koo G; Corey KB; Bluestein SB; Staso PJ; Campbell EM; Phillips EJ
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3807-3810. PubMed ID: 34293499
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients.
    Rojas-Pérez-Ezquerra P; Crespo Quirós J; Tornero Molina P; Baeza Ochoa de Ocáriz ML; Zubeldia Ortuño JM
    J Investig Allergol Clin Immunol; 2021 Apr; 31(2):180-181. PubMed ID: 33648905
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.